title: [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
abstract: In the last couple of years incretin-based antidiabetic drugs became increasingly popular and widely used for treating patients with type 2 diabetes. Immediately after launching, case reports and small case series were published on the potential side effects of the new drugs, with special attention to pancreatic disorders such as acute pancreatitis or pancreatic cancer. As clinical observations accumulated, these side-effects were noted with nearly all drugs of this class. Although these side-effects proved to be rare, an intensive debate evolved in the literature. Opinion of diabetes specialists and representatives of pharmaceutical industry as well as position statements of different international scientific boards and health authorities were published. In addition, results of randomized clinical trials with incretin-based therapy and meta-analyses became available. Importantly, in everyday clinical practice, the label of the given drug should be followed. With regards to incretins, physicians should be cautious if pancreatitis in the patients' past medical history is documented. Early differential diagnosis of any abdominal pain during treatment of incretin-based therapy should be made and the drug should be discontinued if pancreatitis is verified. Continuous post-marketing surveillance and side-effect analysis are still justified with incretin-based antidiabetic treatment in patients with type 2 diabetes.
authors.affiliation: Bajcsy-Zsilinszky Kórház Budapest, Maglódi út 89-91., 1106.
authors.forename: György
authors.initials: G
authors.lastname: Jermendy
mesh_terms: D015746:Abdominal Pain / Q000209:etiology*; D000208:Acute Disease; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003937:Diagnosis, Differential; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D054795:Incretins / Q000008:administration & dosage / Q000009:adverse effects*; D015201:Meta-Analysis as Topic; D010190:Pancreatic Neoplasms / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis*; D010195:Pancreatitis / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents; D054795:Incretins
keywords: DPP-4-gátlók; DPP-4-inhibitors; GLP-1-mimetics; GLP-1-mimetikumok; diabetes mellitus; incretins; inkretinek; pancreas carcinoma; pancreascarcinoma; pancreatitis